Physician profile
Bart Tiberius Hunter
NPI 1437383932
$2,839.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $266 · 2021: $2,124 · 2022: $215 · 2024: $33.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $437.39 | 2019-2022 | |
| Genentech USA, INC. | $394.04 | 2019-2021 | |
| Glaxosmithkline, LLC. | $376.83 | 2021-2022 | |
| Abbvie INC. | $355.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $220.90 | 2021-2024 | |
| Janssen Biotech, INC. | $181.28 | 2021-2022 | |
| Ucb, INC. | $137.17 | 2021 | |
| Lilly USA, LLC | $127.03 | 2021 | |
| Horizon Therapeutics Plc | $122.66 | 2021 | |
| Janssen Scientific Affairs, LLC | $119.79 | 2022 | |
| Radius Health, INC. | $119.10 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $77.60 | 2021 | |
| Genzyme Corporation | $50.32 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $45.07 | 2021 | |
| Pfizer INC. | $34.37 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $16.48 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 | |
| Sobi, INC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.